MedPoint Communications Inc.
announced that it is launching a new service, the Study Document Exchange (SDX) System. This new service aims to optimize the regulatory document completion process by providing a rapid, centralized platform to support the flow of documents among sites, sponsors and CROs.
The SDX system operates stand-alone or within an ePortal, and provides support for single or multiple studies, a compound development program, or an enterprise-wide drug development pipeline. All downloaded documents are tracked for up-to-the-minute accuracy in reporting, and completed forms can be printed for record-keeping and compliance. The SDX system supports electronic signatures, incorporates security features, adheres to 21 CFR Part 11, and is considered a closed system.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.